2018 Nobel Prize Laureates in Physiology or Medicine: James Allison and Tasuku Honjo

The 2018 Nobel Prize in Physiology or Medicine was awarded to James Allison and Tasuku Honjo “for their discovery of cancer therapy by inhibition of negative immune regulation”. However, this year two more immunologists — J.Smith and G.Winter — also became the Nobel Laureates. They received the Award in the “Chemistry” nomination for discovering new approaches to creating proteins with desired properties, including therapeutic antibodies.

Keywords

Nobel Prize, cancer, immunotherapy, immune checkpoints, monoclonal antibody

Received

14.01.2019

Publication date

14.01.2019

Cite Download pdf To download PDF you should sign in

GOST	Nedospasov S. 2018 Nobel Prize Laureates in Physiology or Medicine: James Allison and Tasuku Honjo // Priroda – 2018. – Issue №12 C. 82-86 [Electronic resource]. URL: http://ras.jes.su/priroda/s0032874x0003335-7-1-en (circulation date: 05.11.2024). DOI: 10.31857/S0032874X0003335-7
MLA	Nedospasov, S. "2018 Nobel Prize Laureates in Physiology or Medicine: James Allison and Tasuku Honjo." Priroda 12 (2018):82-86. DOI: 10.31857/S0032874X0003335-7
APA	Nedospasov S. (2018). 2018 Nobel Prize Laureates in Physiology or Medicine: James Allison and Tasuku Honjo. Priroda (12), pp.82-86 DOI: 10.31857/S0032874X0003335-7

Размещенный ниже текст является ознакомительной версией и может не соответствовать печатной

Readers community rating: votes 0

1. McIntyre B.W., Allison J.P. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell. 1983; 34(3): 739–46.

2. Brunet J.F., Denizot F., Luciani M.F. et al. A new member of the immunoglobulin superfamily — CTLA#4. Nature. 1987; 328(6127): 267–270. Doi:10.1038/328267a0.

3. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA#4 blockade. Science. 1996; 271(5256): 1734–1736. Doi:10.1126/science.271.5256.1734.

4. Kwon E.D., Hurwitz A.A., Foster B.A. et. al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. PNAS. 1997; 94(15): 8099–8103. Doi:10.1073/pnas.94.15.8099.

5. Bogolyubova A.V., Efimov G.A., Drutskaya M.S., Nedospasov S.A. Cancer immunotherapy based on the blockade of immune checkpoints. Med. Immunol. 2015; 17(5): 395–406. (In Russ.). Doi:10.15789/1563#0625#2015#5#395#406.

6. Rosenberg S.A., Lotze M.T. Cancer immunotherapy using interleukin#2 and interleukin#2#activated lymphocytes. Annu. Rev. Immunol. 1986; 4: 681–709. Doi:10.1146/annurev.iy.04.040186.003341.

7. Muramatsu M., Kinoshita K., Fagarasan S. … Honjo T. Class switch recombination and hypermutation require activation#induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000; 102(5): 553–563. Doi:10.1016/S0092#8674(00)00078#7.

8. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD#1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11): 3887–3895.